Assessing the Long-Term Effectiveness of Interferon-Beta and Glatiramer Acetate in Multiple Sclerosis: Final 10-Year Results From the UK Multiple Sclerosis Risk-Sharing Scheme

Journal of Neurology, Neurosurgery and Psychiatry - United Kingdom
doi 10.1136/jnnp-2018-318360
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Pnd54 - A Long Term Analysis of the Clinical and Cost Effectiveness of Glatiramer Acetate Using Final 10-Year Results From the Uk Multiple Sclerosis Risk Sharing Scheme

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Long Term Analysis of the Clinical and Cost Effectiveness of Glatiramer Acetate From the Uk Multiple Sclerosis Risk Sharing Scheme

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated With Interferon Beta or Glatiramer Acetate

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2011English

Promoting Oligodendrogenesis and Myelin Repair Using the Multiple Sclerosis Medication Glatiramer Acetate

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis

Journal of Central Nervous System Disease
2012English

Treatment Recommendations for Interferon-Beta in Multiple Sclerosis

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1999English

UK Multiple Sclerosis Risk-Sharing Scheme: A New Natural History Dataset and an Improved Markov Model

BMJ Open
Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy